114 related articles for article (PubMed ID: 1606089)
21. A combined chemo-endocrine treatment with tegafur, adriamycin, methotrexate and tamoxifen for advanced renal cell carcinoma.
Wada T; Houjou T; Kubo R; Yasutomi M; Kurita T
Anticancer Res; 1993; 13(6B):2465-7. PubMed ID: 8135483
[TBL] [Abstract][Full Text] [Related]
22. Medical treatment of metastatic renal cell carcinoma.
Tirelli U; Frustaci S; Galligioni E; Veronesi A; Trovò MG; Magri DM; Crivellari D; Roncadin M; Tumolo S; Grigoletto E
Tumori; 1980 Apr; 66(2):235-40. PubMed ID: 7445105
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer.
Zaniboni A; Simoncini E; Marpicati P; Montini E; Ferrari V; Marini G
J Chemother; 1989 Oct; 1(5):350-1. PubMed ID: 2585035
[TBL] [Abstract][Full Text] [Related]
24. Combined chemoendocrine treatment with tegafur and tamoxifen for advanced renal cell carcinoma.
Wada T; Nishiyama K; Maeda M; Hara S; Tanaka N; Yasutomi M; Kurita T
Anticancer Res; 1995; 15(4):1581-4. PubMed ID: 7654050
[TBL] [Abstract][Full Text] [Related]
25. Cytokines in combination with chemotherapy for advanced renal carcinoma--the importance of patient selection.
Joffe JK; Patel PM; Banks RE; Selby PJ
Cancer Biother Radiopharm; 1996 Oct; 11(5):309-13. PubMed ID: 10851510
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer.
Hussain M; Vaishampayan U; Heilbrun LK; Jain V; LoRusso PM; Ivy P; Flaherty L
Invest New Drugs; 2003 Nov; 21(4):465-71. PubMed ID: 14586215
[TBL] [Abstract][Full Text] [Related]
27. Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma.
Mani S; Poo WJ
Am J Clin Oncol; 1996 Apr; 19(2):149-53. PubMed ID: 8610639
[TBL] [Abstract][Full Text] [Related]
28. Interferon alpha 2b as medical selection for nephrectomy in patients with synchronous metastatic renal cell carcinoma: a consecutive study.
Bex A; Kerst M; Mallo H; Meinhardt W; Horenblas S; de Gast GC
Eur Urol; 2006 Jan; 49(1):76-81. PubMed ID: 16310929
[TBL] [Abstract][Full Text] [Related]
29. A phase II trial of pemetrexed in patients with metastatic renal cancer.
Thödtmann R; Sauter T; Weinknecht S; Weissbach L; Blatter J; Ohnmacht U; Hanauske A
Invest New Drugs; 2003 Aug; 21(3):353-8. PubMed ID: 14578684
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
[TBL] [Abstract][Full Text] [Related]
31. Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma.
Obara W; Mizutani Y; Oyama C; Akaza H; Ishii N; Kohri K; Namiki M; Okuyama A; Shima H; Yokoyama M; Shuin T; Miki T; Watanabe Y; Fujioka T
Int J Urol; 2008 Sep; 15(9):794-9. PubMed ID: 18651865
[TBL] [Abstract][Full Text] [Related]
32. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Lara PN; Quinn DI; Margolin K; Meyers FJ; Longmate J; Frankel P; Mack PC; Turrell C; Valk P; Rao J; Buckley P; Wun T; Gosselin R; Galvin I; Gumerlock PH; Lenz HJ; Doroshow JH; Gandara DR;
Clin Cancer Res; 2003 Oct; 9(13):4772-81. PubMed ID: 14581348
[TBL] [Abstract][Full Text] [Related]
33. [A combined chemo-endocrine therapy with tegafur, adriamycin, methotrexate and tamoxifen for advanced renal cell carcinoma].
Wada T; Morikawa E; Yasutomi M; Takagi H; Aizawa M; Abe T; Wada A
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1652-6. PubMed ID: 2230447
[TBL] [Abstract][Full Text] [Related]
34. [First Hungarian experience with pazopanib therapy for patients with metastatic renal cancer].
Maráz A; Bodrogi I; Csejtei A; Dank M; Géczi L; Küronya Z; Mangel L; Petrányi A; Szûcs M; Bodoky G
Magy Onkol; 2013 Sep; 57(3):173-6. PubMed ID: 24107823
[TBL] [Abstract][Full Text] [Related]
35. Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan.
Koie T; Ohyama C; Yoneyama T; Yamamoto H; Imai A; Hatakeyama S; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
BMC Urol; 2015 Apr; 15():32. PubMed ID: 25887125
[TBL] [Abstract][Full Text] [Related]
36. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
[TBL] [Abstract][Full Text] [Related]
37. High-dose interleukin 2 in patients with metastatic renal cell carcinoma with sarcomatoid features.
Achkar T; Arjunan A; Wang H; Saul M; Davar D; Appleman LJ; Friedland D; Parikh RA
PLoS One; 2017; 12(12):e0190084. PubMed ID: 29261796
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.
Miyake H; Hara I; Sakai I; Harada K; Inoue TA; Eto H; Takechi Y; Fujisawa M
Int J Clin Oncol; 2005 Oct; 10(5):338-41. PubMed ID: 16247661
[TBL] [Abstract][Full Text] [Related]
39. A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma.
Krzyzanowska MK; Tannock IF; Lockwood G; Knox J; Moore M; Bjarnason GA
Cancer Chemother Pharmacol; 2007 Jun; 60(1):135-41. PubMed ID: 17009033
[TBL] [Abstract][Full Text] [Related]
40. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
